Graft-versus-host disease treatment aims to achieve immune tolerance, suppress pathogenic donor T-cell activity, and protect host tissues while preserving essential graft-versus-leukemia effects. Medical management relies on precise grading using international donor recipient scoring systems and incorporates systemic corticosteroids, Janus kinase inhibitors, kinase modulators, and photopheresis depending on acute or chronic disease classification.

GVHD treatment protocols begin with baseline organ function assessments and histological tissue validation. First-line therapy consists of oral or intravenous high-dose corticosteroids (typically methylprednisolone or prednisone at 1 to 2 milligrams per kilogram per day). Response is evaluated over 3 to 14 days using standardized criteria such as the Harris or NIH response standards. In steroid-refractory or steroid-dependent cases, second-line therapies are added. These include Janus kinase (JAK) inhibitors such as ruxolitinib, Rho-associated coiled-coil kinase 2 (ROCK2) inhibitors such as belumosudil, Bruton tyrosine kinase (BTK) inhibitors, extracorporeal photopheresis (ECP), or calcineurin inhibitors. Local therapies, including topical corticosteroids, non-absorbable GI steroids (budesonide), and specialized ophthalmic drops, are co-administered to control localized organ manifestations.

Evidence-based GVHD treatment suppresses damaging immune responses, restores organ functionality, reduces long-term tissue fibrosis, and improves overall post-transplant survival. Timely administration of targeted second-line agents offers response rates of 50% to 70% in steroid-refractory settings, according to clinical trial data (Zeiser et al., NEJM 2020; Cutler et al., Blood 2021).

Recovery from acute or chronic GVHD is an extended clinical process ranging from several months to years. Systemic immunosuppression is tapered cautiously based on objective clinical organ response scores. Ongoing rehabilitation involves dermatological care, physical therapy for sclerotic joint contractures, pulmonary monitoring, and serial infection screening to ensure safe immune reconstitution.

GVHD treatment addresses both acute graft-versus-host disease (aGVHD) and chronic graft-versus-host disease (cGVHD) arising after allogeneic hematopoietic cell transplantation. Indications include cutaneous eruptions, cholestatic liver dysfunction, severe gastrointestinal mucosal inflammation, pulmonary bronchiolitis obliterans syndrome, ocular dry eye syndrome, neuromuscular weakness, and sclerotic skin contractures.

Preparation for GVHD therapy requires baseline objective organ evaluation, including skin staging percentage, total bilirubin levels, daily stool volume measurement, pulmonary function tests with diffusion capacity, and tissue biopsies when clinically feasible. Comprehensive infectious disease screening is performed, encompassing cytomegalovirus (CMV) quantitative PCR, Epstein-Barr virus (EBV) screening, hepatitis serologies, and fungal baseline imaging. Patients are initiated on anti-infective prophylaxis, including trimethoprim-sulfamethoxazole for Pneumocystis jirovecii, acyclovir or valacyclovir for herpes simplex/zoster, and mold-active triazoles for invasive fungal prevention. Baseline bone density scanning, glucose monitoring, and blood pressure evaluation are established prior to high-dose corticosteroid initiation.

Complications associated with GVHD treatment stem primarily from systemic immunosuppression and target-specific drug toxicities. Severe opportunistic infections—including invasive fungal infections, cytomegalovirus reactivation, and bacterial sepsis—represent major adverse risks. Systemic steroid toxicity includes hypercortisolemia, steroid-induced diabetes mellitus, secondary hypertension, proximal myopathy, osteonecrosis, mood instability, and posterior subcapsular cataracts. Second-line agent risks include cytopenias, transaminitis, gastrointestinal disturbances, and hypertriglyceridemia. Inadequate control of chronic GVHD can lead to progressive pulmonary fibrosis, severe joint mobility loss from scleroderma-like changes, and secondary malignancies.

The clinical trajectory of GVHD treatment begins with pre-transplant risk assessment and prophylactic immunosuppression, followed by close post-transplant monitoring for early cutaneous, gastrointestinal, or hepatic signs. Upon clinical diagnosis and biopsy confirmation, patients initiate first-line systemic therapy. Refractory or progressive disease prompts transition to second-line targeted agents or cellular therapies, requiring long-term multidisciplinary monitoring for infection risks, secondary organ toxicity, and tissue rehabilitation.